CD22 and neoplasm: Interestingly, compared to the control group, FCM analysis at 96 h showed that pretreatment of tumor cells with rituximab did not significantly upregulate CD19/CD22 CAR-T surface exhaustion molecules (PD-1, TIM-3) (Fig. 5A–C).